Theme watch · accelerating
Medtech stocks to watch · October 2026.
As of 11 October 2026
GRAIL's shares already price in FDA approval of its Galleri cancer blood test and slipped to $132.61 on 8 October 2026 as new trial data arrived.…
Myriad Genetics shares trade on one broker's $8 recovery call while revenue per test is still falling; the third-quarter report, expected around 2…
Illumina's clinical sequencing recovery is intact, but the shares slid to $264.57 on 8 October 2026 after reversing from a $309.35 intraday high…
CareDx's shares have more than doubled in three months on a raised 2026 revenue guide and a higher preliminary Medicare rate for AlloSure; the…
Intuitive Surgical's revenue grew 19% last quarter while its shares trade 29.9% below their 52-week high; the 20 October 2026 third-quarter report…
Quanterix's shares, at $3.21 on 8 October 2026, still trade above the $3.00 consensus target despite reduced $142–148 million 2026 revenue…
Revvity's case rests on AI drug-discovery customers turning a record instrument backlog into Life Sciences growth; the 3 November 2026…
Twist Bioscience's 23% revenue growth as an AI antibody-data supplier is real, but its shares fell to a $152.05 close on 8 October 2026, 25.8%…
"3-mo price move" is the stock's market price change, not a FrontierPicks return. The "3-mo price move" column is one of the three inputs to that score, weighted 20% — not the ranking itself, so rows do not descend in it. A dash means the name did not place in this week’s top-50 momentum scan, so it has no published 3-month figure.
How this page is built
These are the names FrontierPicks covers in the medtech stocks theme, each with a dated research dossier. Names on the momentum board rank first by a composite momentum score — 1-month price trend 50%, 3-month trend 20% and acceleration 30% — computed arithmetically from daily closing prices, through the last completed session, then the rest by conviction. The research decides which stocks belong to each theme; this one currently reads as accelerating.
Questions
- What medtech stocks does FrontierPicks cover?
- As of 11 October 2026, the medtech stocks FrontierPicks tracks are led by GRAL, MYGN, ILMN, CDNA, each with a dated research dossier. Names on the momentum board rank first by composite momentum score, then the rest by conviction.
- Is the medtech stocks theme accelerating or slowing?
- FrontierPicks reads this theme as accelerating as of 11 October 2026. Diagnostics and genomics names are rising on dated clinical and regulatory news: GRAIL (GRAL) said on Oct. 5 it will present new NHS-Galleri trial data at ESMO, Quanterix (QTRX) won Chinese regulatory approval for its Simoa neurology testing on Oct. 7, and Myriad Genetics (MYGN) announced a prostate cancer genomic score collaboration with SOPHiA GENETICS on Oct. 8. The theme is still accelerating: GRAIL is up 71.2% over one month, and the sell-side keeps adding coverage, with William Blair initiating Revvity (RVTY) at Outperform on Oct. 6 and Barclays initiating Intuitive Surgical (ISRG) at Overweight with a $485 target on Oct. 7. Revvity, Mettler-Toledo (MTD) and Intuitive Surgical join the group this week, and Natera (NTRA) dropped off the leader list.
- How does FrontierPicks rank medtech stocks?
- Every name links to its dated research dossier. Names on the momentum board rank first by composite momentum score, then the rest by conviction. The full method is on the methodology page.
Related
As of 11 October 2026